ASSOCIATION BETWEEN MICROBES AND IBD (CROHN’S DISEASE) AND THEIR SENSITIVITY/RESISTANCE TO DRUGS
Main Article Content
Keywords
Crohn’s Disease, Gut Microbiota, Escherichia coli, Faecalibacterium prausnitzii, Immune dysregulation, SCFAs, Immune dysregulation, Inflammation
Abstract
Immune dysregulation and an imbalance in the gut microbiota are hallmarks of Crohn's disease (CD), a chronic, recurrent gastrointestinal disorder that is a subset of inflammatory bowel disease (IBD). The intricate interactions among host genetics, environmental variables, microbial dysbiosis, and immunological responses in CD pathogenesis are examined in this study. Recent research highlights a marked decline in microbial diversity and a move toward pro-inflammatory microbial communities in CD patients, including decreased Faecalibacterium prausnitzii and elevated Escherichia coli. The article describes the structural and functional functions of important gut microbes in health and how immune activation, chronic inflammation, and mucosal barrier dysfunction are all impacted by their alteration. Additionally, it looks at how biologics and antibiotics affect microbial resistance and composition, emphasizing both the therapeutic advantages and unforeseen side effects such dysbiosis and multidrug resistance. The report also highlights how precision medicine techniques, like bacteriophage therapy, targeted microbial therapies, and microbial sensitivity profiling, have potential for improving CD care. Developing tailored treatments and enhancing long-term results for Crohn's disease require a thorough grasp of gut microbial dynamics and resistance mechanisms.
References
1. Alimuddin, Z. (2006). Infectious diseases. (Infectious diseases.). Current Opinion in Pulmonary Medicine, 12(3), 165–249. https://doi.org/10.1016/j.mib.2014.05.022.Bacteriophage-based
2. Antoni, L., Nuding, S., Wehkamp, J., & Stange, E. F. (2014). Intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 20(5), 1165–1179. https://doi.org/10.3748/wjg.v20.i5.1165
3. Baumgart, D. C., & Sandborn, W. J. (2012). Crohn’s disease. The Lancet, 380(9853), 1590–1605. https://doi.org/10.1016/S0140-6736(12)60026-9
4. Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011
5. Chelakkot, C., Ghim, J., & Ryu, S. H. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental and Molecular Medicine, 50(8). https://doi.org/10.1038/s12276-018-0126-x
6. Cheng, F., Huang, Z., Wei, W., & Li, Z. (2021). Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology, 25(5), 495–504. https://doi.org/10.1007/s10151-020-02395-3
7. Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., & Finlay, B. B. (2013). Recent advances in understanding enteric pathogenic Escherichia coli. Clinical Microbiology Reviews, 26(4), 822–880. https://doi.org/10.1128/CMR.00022-13
8. Derrien, M., Vaughan, E. E., Plugge, C. M., & de Vos, W. M. (2004). Akkermansia municiphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. International Journal of Systematic and Evolutionary Microbiology, 54(5), 1469–1476. https://doi.org/10.1099/ijs.0.02873-0
9. Dethlefsen, L., & Relman, D. A. (2010). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. https://doi.org/10.1073/pnas.1000087107/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1000087107
10. Droz, D., Diebold, N., Jan, D., & Jaubert, F. (1990). Deduction from Wilms’ tumour that glomerular podocytes produce the basement membrane material bearing goodpasture determinants. The Journal of Pathology, 162(4), 323–327. https://doi.org/10.1002/path.1711620408
11. Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., Hanauer, S. B., & McDonald, J. W. D. (1995). Methotrexate for the Treatment of Crohn’s Disease. New England Journal of Medicine, 332(5), 292–297. https://doi.org/10.1056/nejm199502023320503
12. Feller, M., Huwiler, K., Schoepfer, A., Shang, A., Furrer, H., & Egger, M. (2010). Long-term antibiotic treatment for Crohn’s disease: Systematic review and meta-analysis of placebo-controlled trials. Clinical Infectious Diseases, 50(4), 473–480. https://doi.org/10.1086/649923
13. Fetter, K., Weigel, M., Ott, B., Fritzenwanker, M., Stricker, S., de Laffolie, J., & Hain, T. (2023). The microbiome landscape in pediatric Crohn’s disease and therapeutic implications. Gut Microbes, 15(2). https://doi.org/10.1080/19490976.2023.2247019
14. Filippo, C. De, Cavalieri, D., Di, M., Ramazzotti, M., & Baptiste, J. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. 107(33). https://doi.org/10.1073/pnas.1005963107
15. Frank, D. N., Amand, A. L. S., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.
16. Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., Morgan, X. C., Kostic, A. D., Luo, C., González, A., McDonald, D., Haberman, Y., Walters, T., Baker, S., Rosh, J., … Xavier, R. J. (2014). The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host and Microbe, 15(3), 382–392. https://doi.org/10.1016/j.chom.2014.02.005
17. Guan, Q. (2019). A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019. https://doi.org/10.1155/2019/7247238
18. Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., Creasy, H. H., Earl, A. M., Fitzgerald, M. G., Fulton, R. S., Giglio, M. G., Hallsworth-Pepin, K., Lobos, E. A., Madupu, R., Magrini, V., Martin, J. C., Mitreva, M., Muzny, D. M., Sodergren, E. J., … White, O. (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486(7402), 207–214. https://doi.org/10.1038/nature11234
19. Iliev, I. D., Funari, V. A., Taylor, K. D., Nguyen, Q., Reyes, C. N., Strom, S. P., Brown, J., Becker, C. A., Fleshner, P. R., Dubinsky, M., Rotter, J. I., Wang, H. L., McGovern, D. P. B., Brown, G. D., & Underhill, D. M. (2012). Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science, 336(6086), 1314–1317. https://doi.org/10.1126/science.1221789
20. Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Schumm, L. P., Sharma, Y., Anderson, C. A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S. L., Raychaudhuri, S., Goyette, P., Wei, Z., … Cho, J. H. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119–124. https://doi.org/10.1038/nature11582
21. Khor, B., Gardet, A., & Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature, 474(7351), 307–317. https://doi.org/10.1038/nature10209
22. Knights, D., Silverberg, M. S., Weersma, R. K., Gevers, D., Dijkstra, G., Huang, H., Tyler, A. D., Van Sommeren, S., Imhann, F., Stempak, J. M., Huang, H., Vangay, P., Al-Ghalith, G. A., Russell, C., Sauk, J., Knight, J., Daly, M. J., Huttenhower, C., & Xavier, R. J. (2014). Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Medicine, 6(12), 1–11. https://doi.org/10.1186/s13073-014-0107-1
23. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041
24. Leblanc, J. G., Milani, C., Giori, G. S. De, Sesma, F., Sinderen, D. Van, & Ventura, M. (2013). Bacteria as vitamin suppliers to their host : a gut microbiota perspective. Current Opinion in Biotechnology, 24(2), 160–168. https://doi.org/10.1016/j.copbio.2012.08.005
25. Levine, B., Mizushima, N., & Virgin, H. W. (2011). Autophagy in immunity and inflammation. Nature, 469(7330), 323–335. https://doi.org/10.1038/nature09782
26. Lewis, J. D., Chen, E. Z., Baldassano, R. N., Otley, A. R., Griffiths, A. M., Lee, D., Bittinger, K., Bailey, A., Friedman, E. S., Hoffmann, C., Albenberg, L., Sinha, R., Compher, C., Gilroy, E., Nessel, L., Grant, A., Chehoud, C., Li, H., Wu, G. D., & Bushman, F. D. (2017). Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn’s Disease. Cell Host & Microbe, 22(2), 247. https://doi.org/10.1016/j.chom.2017.07.011
27. Lipton, J. O., Yuan, E. D., Asara, J. M., Sahin, M., Lipton, J. O., Yuan, E. D., Boyle, L. M., Ebrahimi-fakhari, D., Kwiatkowski, E., Nathan, A., Davis, F., Asara, J. M., & Sahin, M. (n.d.). The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation Article The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation. 1–14. https://doi.org/10.1016/j.cell.2015.04.002
28. Littman, D. R. (n.d.). The Microbiome in Infectious Disease and Inflammation. https://doi.org/10.1146/annurev-immunol-020711-074937
29. Longman, R. S., & Swaminath, A. (2013). Microbial manipulation as primary therapy for Crohn’s disease. World Journal of Gastroenterology, 19(10), 1513–1516. https://doi.org/10.3748/wjg.v19.i10.1513
30. Louis, P., & Flint, H. J. (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiology Letters, 294(1), 1–8. https://doi.org/10.1111/j.1574-6968.2009.01514.x
31. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012). Diversity , stability and resilience of the human gut microbiota. https://doi.org/10.1038/nature11550
32. Lynch, S. V., & Pedersen, O. (2016). The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine, 375(24), 2369–2379. https://doi.org/10.1056/nejmra1600266
33. Macfarlane, S., & Macfarlane, G. T. (2003). Regulation of short-chain fatty acid production. Proceedings of the Nutrition Society, 62(1), 67–72. https://doi.org/10.1079/pns2002207
34. Mahony, S. M. O., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009). Microbiota in Rats : Implications for Irritable Bowel Syndrome and Psychiatric Illnesses. BPS, 65(3), 263–267. https://doi.org/10.1016/j.biopsych.2008.06.026
35. Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012). The gut microbiota in IBD. 9(October), 599–608. https://doi.org/10.1038/nrgastro.2012.152
36. Marks, D. J. B., Rahman, F. Z., Sewell, G. W., & Segal, A. W. (2015). Europe PMC Funders Group Crohn ’ s Disease : an Immune Deficiency State. 38(1), 20–31. https://doi.org/10.1007/s12016-009-8133-2.Crohn
37. Migliore, F., Macchi, R., Landini, P., & Paroni, M. (2018). Phagocytosis and epithelial cell invasion by Crohn’s disease-associated adherent-invasive Escherichia coli are inhibited by the anti-inflammatory drug 6-mercaptopurine. Frontiers in Microbiology, 9(MAY), 1–15. https://doi.org/10.3389/fmicb.2018.00964
38. Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V, Reyes, J. A., Shah, S. A., Leleiko, N., Snapper, S. B., Bousvaros, A., Korzenik, J., Sands, B. E., Xavier, R. J., & Huttenhower, C. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
39. Muzes, G., Molnár, B., Tulassay, Z., & Sipos, F. (2012). Changes of the cytokine profile in inflammatory bowel diseases. World Journal of Gastroenterology, 18(41), 5848–5861. https://doi.org/10.3748/wjg.v18.i41.5848
40. Nash, A. K., Auchtung, T. A., Wong, M. C., Smith, D. P., Gesell, J. R., Ross, M. C., Stewart, C. J., Metcalf, G. A., Muzny, D. M., Gibbs, R. A., Ajami, N. J., & Petrosino, J. F. (2017). The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome, 5(1), 153. https://doi.org/10.1186/s40168-017-0373-4
41. Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., Sung, J. J. Y., & Kaplan, G. G. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet, 390(10114), 2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0
42. Nguyen, H. T. T., Dalmasso, G., Müller, S., Carrière, J., Seibold, F., & Darfeuille-Michaud, A. (2014). Crohn’s disease-associated adherent invasive escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology, 146(2), 508–519. https://doi.org/10.1053/j.gastro.2013.10.021
43. Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2018). Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, 11(1). https://doi.org/10.1007/s12328-017-0813-5
44. Orel, R., & Trop, T. K. (2014). Intestinal microbiota , probiotics and prebiotics in inflammatory bowel disease. 20(33), 11505–11524. https://doi.org/10.3748/wjg.v20.i33.11505
45. Palmela, C., Chevarin, C., Xu, Z., Torres, J., Sevrin, G., Hirten, R., Barnich, N., Ng, S. C., & Colombel, J. F. (2018). Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 67(3), 574–587. https://doi.org/10.1136/gutjnl-2017-314903
46. Petersen, C., & Round, J. L. (2014). Microreview Defining dysbiosis and its influence on host immunity and disease. 16(June), 1024–1033. https://doi.org/10.1111/cmi.12308
47. Pu, D., Zhang, Z., & Feng, B. (2022). Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Frontiers in Pharmacology, 13(June). https://doi.org/10.3389/fphar.2022.906419
48. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., … Zoetendal, E. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464(7285), 59–65. https://doi.org/10.1038/nature08821
49. Qusty, N., Sarhan, A., Taha, M., Alshanqiti, A., Almuteb, A. M., Alfaraidi, A. T., Alkhairi, H. A., Alzahrani, M. M., Alamry, A. H. A., Qalil, T., Alomry, B., Bannan, O. A., & Almaashi, M. S. (2024). The Role of Gut Microbiota in the Efficacy and Side Effect Profile of Biologic Therapies for Autoimmune Diseases. 16(10), 1–9. https://doi.org/10.7759/cureus.71111
50. Rashed, R., Valcheva, R., & Dieleman, L. A. (2022). Manipulation of Gut Microbiota as a Key Target for Crohn’s Disease. Frontiers in Medicine, 9(June). https://doi.org/10.3389/fmed.2022.887044
51. Reinecker, H., Steffen, M., Witthoeft, T., Pflueger, I., & Schreiber, S. (1993).. 174–181.
52. Reyes, A., Haynes, M., Hanson, N., Angly, F. E., Heath, A. C., Rohwer, F., & Gordon, J. I. (2010). Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature, 466(7304), 334–338. https://doi.org/10.1038/nature09199
53. Ridlon, J. M., Kang, D., & Hylemon, P. B. (2006). review Bile salt biotransformations by human intestinal bacteria. 47, 241–259. https://doi.org/10.1194/jlr.R500013-JLR200
54. Round, J. L., & Mazmanian, S. K. (2010a). Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. 2010. https://doi.org/10.1073/pnas.0909122107/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.0909122107
55. Round, J. L., & Mazmanian, S. K. (2010b). Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. 2010. https://doi.org/10.1073/pnas.0909122107
56. Samuel, B. S., & Gordon, J. I. (2006). A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proceedings of the National Academy of Sciences of the United States of America, 103(26), 10011–10016. https://doi.org/10.1073/pnas.0602187103
57. Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008). Role of cytokines in inflammatory bowel disease. World Journal of Gastroenterology, 14(27), 4280–4288. https://doi.org/10.3748/wjg.14.4280
58. Satsangi, J., Kennedy, N. A., Henderson, P., Wilson, D. C., & Nimmo, E. R. (2011). Exploring the hidden heritability of inflammatory bowel disease. Gut, 60(11), 1447–1448. https://doi.org/10.1136/gutjnl-2011-300804
59. Sender, R., Fuchs, S., & Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biology, 14(8), 1–14. https://doi.org/10.1371/journal.pbio.1002533
60. Shah, T., Baloch, Z., Shah, Z., Cui, X., & Xia, X. (2021). The intestinal microbiota: Impacts of antibiotics therapy, colonization resistance, and diseases. International Journal of Molecular Sciences, 22(12). https://doi.org/10.3390/ijms22126597
61. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). Review The Central Nervous System and the Gut Microbiome. Cell, 167(4), 915–932. https://doi.org/10.1016/j.cell.2016.10.027
62. Singh, N., & Bernstein, C. N. (2022). Environmental risk factors for inflammatory bowel disease. United European Gastroenterology Journal, 10(10), 1047–1053. https://doi.org/10.1002/ueg2.12319
63. Sitaraman, S. V. (2008). IL-6 Induces NF-. 171(2003), 3194–3201.
64. Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P., & Doraé, J. (2009). Low counts of faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases, 15(8), 1183–1189. https://doi.org/10.1002/ibd.20903
65. Sousa, R. S. (2014). Caraterização do Acesso ao Centro Hospitalar Lisboa Norte , EPE Caraterização do Acesso ao Centro Hospitalar Lisboa Norte , EPE. 104(18).
66. Tenaillon, O., Skurnik, D., Picard, B., & Denamur, E. (2010). The population genetics of commensal Escherichia coli. Nature Reviews Microbiology, 8(3), 207–217. https://doi.org/10.1038/nrmicro2298
67. Thursby, E., & Juge, N. (2017). Introduction to the human gut microbiota. Biochemical Journal, 474(11), 1823–1836. https://doi.org/10.1042/BCJ20160510
68. Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1
69. Turroni, F., Milani, C., Duranti, S., Ferrario, C., Lugli, G. A., Mancabelli, L., van Sinderen, D., & Ventura, M. (2018). Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cellular and Molecular Life Sciences, 75(1), 103–118. https://doi.org/10.1007/s00018-017-2672-0
70. Wang, K., Wu, L. Y., Dou, C. Z., Guan, X., Wu, H. G., & Liu, H. R. (2016). Research Advance in Intestinal Mucosal Barrier and Pathogenesis of Crohn’s Disease. Gastroenterology Research and Practice, 2016. https://doi.org/10.1155/2016/9686238
71. Wexler, H. M. (2007). Bacteroides: The good, the bad, and the nitty-gritty. Clinical Microbiology Reviews, 20(4), 593–621. https://doi.org/10.1128/CMR.00008-07
72. Wright, E. K., Kamm, M. A., Teo, S. M., Inouye, M., Wagner, J., & Kirkwood, C. D. (2015). Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn ’ s Disease : A Systematic Review. 21(6), 1219–1228. https://doi.org/10.1097/MIB.0000000000000382
73. Wu, N., Mah, C., Koentgen, S., Zhang, L., Grimm, M. C., El-Omar, E., & Hold, G. L. (2021). Inflammatory bowel disease and the gut microbiota. Proceedings of the Nutrition Society, 80(4), 424–434. https://doi.org/10.1017/S002966512100197X
74. Zhao, S., Lieberman, T. D., Poyet, M., Kauffman, K. M., Gibbons, S. M., Groussin, M., Xavier, R. J., & Alm, E. J. (2019). Adaptive Evolution within Gut Microbiomes of Healthy People. Cell Host and Microbe, 25(5), 656-667.e8. https://doi.org/10.1016/j.chom.2019.03.007
75. Zuo, T., & Ng, S. C. (2018). The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. 9(September), 1–13. https://doi.org/10.3389/fmicb.2018.02247
2. Antoni, L., Nuding, S., Wehkamp, J., & Stange, E. F. (2014). Intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 20(5), 1165–1179. https://doi.org/10.3748/wjg.v20.i5.1165
3. Baumgart, D. C., & Sandborn, W. J. (2012). Crohn’s disease. The Lancet, 380(9853), 1590–1605. https://doi.org/10.1016/S0140-6736(12)60026-9
4. Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011
5. Chelakkot, C., Ghim, J., & Ryu, S. H. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental and Molecular Medicine, 50(8). https://doi.org/10.1038/s12276-018-0126-x
6. Cheng, F., Huang, Z., Wei, W., & Li, Z. (2021). Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology, 25(5), 495–504. https://doi.org/10.1007/s10151-020-02395-3
7. Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., & Finlay, B. B. (2013). Recent advances in understanding enteric pathogenic Escherichia coli. Clinical Microbiology Reviews, 26(4), 822–880. https://doi.org/10.1128/CMR.00022-13
8. Derrien, M., Vaughan, E. E., Plugge, C. M., & de Vos, W. M. (2004). Akkermansia municiphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. International Journal of Systematic and Evolutionary Microbiology, 54(5), 1469–1476. https://doi.org/10.1099/ijs.0.02873-0
9. Dethlefsen, L., & Relman, D. A. (2010). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. https://doi.org/10.1073/pnas.1000087107/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1000087107
10. Droz, D., Diebold, N., Jan, D., & Jaubert, F. (1990). Deduction from Wilms’ tumour that glomerular podocytes produce the basement membrane material bearing goodpasture determinants. The Journal of Pathology, 162(4), 323–327. https://doi.org/10.1002/path.1711620408
11. Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., Hanauer, S. B., & McDonald, J. W. D. (1995). Methotrexate for the Treatment of Crohn’s Disease. New England Journal of Medicine, 332(5), 292–297. https://doi.org/10.1056/nejm199502023320503
12. Feller, M., Huwiler, K., Schoepfer, A., Shang, A., Furrer, H., & Egger, M. (2010). Long-term antibiotic treatment for Crohn’s disease: Systematic review and meta-analysis of placebo-controlled trials. Clinical Infectious Diseases, 50(4), 473–480. https://doi.org/10.1086/649923
13. Fetter, K., Weigel, M., Ott, B., Fritzenwanker, M., Stricker, S., de Laffolie, J., & Hain, T. (2023). The microbiome landscape in pediatric Crohn’s disease and therapeutic implications. Gut Microbes, 15(2). https://doi.org/10.1080/19490976.2023.2247019
14. Filippo, C. De, Cavalieri, D., Di, M., Ramazzotti, M., & Baptiste, J. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. 107(33). https://doi.org/10.1073/pnas.1005963107
15. Frank, D. N., Amand, A. L. S., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.
16. Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., Morgan, X. C., Kostic, A. D., Luo, C., González, A., McDonald, D., Haberman, Y., Walters, T., Baker, S., Rosh, J., … Xavier, R. J. (2014). The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host and Microbe, 15(3), 382–392. https://doi.org/10.1016/j.chom.2014.02.005
17. Guan, Q. (2019). A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019. https://doi.org/10.1155/2019/7247238
18. Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., Creasy, H. H., Earl, A. M., Fitzgerald, M. G., Fulton, R. S., Giglio, M. G., Hallsworth-Pepin, K., Lobos, E. A., Madupu, R., Magrini, V., Martin, J. C., Mitreva, M., Muzny, D. M., Sodergren, E. J., … White, O. (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486(7402), 207–214. https://doi.org/10.1038/nature11234
19. Iliev, I. D., Funari, V. A., Taylor, K. D., Nguyen, Q., Reyes, C. N., Strom, S. P., Brown, J., Becker, C. A., Fleshner, P. R., Dubinsky, M., Rotter, J. I., Wang, H. L., McGovern, D. P. B., Brown, G. D., & Underhill, D. M. (2012). Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science, 336(6086), 1314–1317. https://doi.org/10.1126/science.1221789
20. Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Schumm, L. P., Sharma, Y., Anderson, C. A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S. L., Raychaudhuri, S., Goyette, P., Wei, Z., … Cho, J. H. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119–124. https://doi.org/10.1038/nature11582
21. Khor, B., Gardet, A., & Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature, 474(7351), 307–317. https://doi.org/10.1038/nature10209
22. Knights, D., Silverberg, M. S., Weersma, R. K., Gevers, D., Dijkstra, G., Huang, H., Tyler, A. D., Van Sommeren, S., Imhann, F., Stempak, J. M., Huang, H., Vangay, P., Al-Ghalith, G. A., Russell, C., Sauk, J., Knight, J., Daly, M. J., Huttenhower, C., & Xavier, R. J. (2014). Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Medicine, 6(12), 1–11. https://doi.org/10.1186/s13073-014-0107-1
23. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041
24. Leblanc, J. G., Milani, C., Giori, G. S. De, Sesma, F., Sinderen, D. Van, & Ventura, M. (2013). Bacteria as vitamin suppliers to their host : a gut microbiota perspective. Current Opinion in Biotechnology, 24(2), 160–168. https://doi.org/10.1016/j.copbio.2012.08.005
25. Levine, B., Mizushima, N., & Virgin, H. W. (2011). Autophagy in immunity and inflammation. Nature, 469(7330), 323–335. https://doi.org/10.1038/nature09782
26. Lewis, J. D., Chen, E. Z., Baldassano, R. N., Otley, A. R., Griffiths, A. M., Lee, D., Bittinger, K., Bailey, A., Friedman, E. S., Hoffmann, C., Albenberg, L., Sinha, R., Compher, C., Gilroy, E., Nessel, L., Grant, A., Chehoud, C., Li, H., Wu, G. D., & Bushman, F. D. (2017). Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn’s Disease. Cell Host & Microbe, 22(2), 247. https://doi.org/10.1016/j.chom.2017.07.011
27. Lipton, J. O., Yuan, E. D., Asara, J. M., Sahin, M., Lipton, J. O., Yuan, E. D., Boyle, L. M., Ebrahimi-fakhari, D., Kwiatkowski, E., Nathan, A., Davis, F., Asara, J. M., & Sahin, M. (n.d.). The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation Article The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation. 1–14. https://doi.org/10.1016/j.cell.2015.04.002
28. Littman, D. R. (n.d.). The Microbiome in Infectious Disease and Inflammation. https://doi.org/10.1146/annurev-immunol-020711-074937
29. Longman, R. S., & Swaminath, A. (2013). Microbial manipulation as primary therapy for Crohn’s disease. World Journal of Gastroenterology, 19(10), 1513–1516. https://doi.org/10.3748/wjg.v19.i10.1513
30. Louis, P., & Flint, H. J. (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiology Letters, 294(1), 1–8. https://doi.org/10.1111/j.1574-6968.2009.01514.x
31. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012). Diversity , stability and resilience of the human gut microbiota. https://doi.org/10.1038/nature11550
32. Lynch, S. V., & Pedersen, O. (2016). The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine, 375(24), 2369–2379. https://doi.org/10.1056/nejmra1600266
33. Macfarlane, S., & Macfarlane, G. T. (2003). Regulation of short-chain fatty acid production. Proceedings of the Nutrition Society, 62(1), 67–72. https://doi.org/10.1079/pns2002207
34. Mahony, S. M. O., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009). Microbiota in Rats : Implications for Irritable Bowel Syndrome and Psychiatric Illnesses. BPS, 65(3), 263–267. https://doi.org/10.1016/j.biopsych.2008.06.026
35. Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012). The gut microbiota in IBD. 9(October), 599–608. https://doi.org/10.1038/nrgastro.2012.152
36. Marks, D. J. B., Rahman, F. Z., Sewell, G. W., & Segal, A. W. (2015). Europe PMC Funders Group Crohn ’ s Disease : an Immune Deficiency State. 38(1), 20–31. https://doi.org/10.1007/s12016-009-8133-2.Crohn
37. Migliore, F., Macchi, R., Landini, P., & Paroni, M. (2018). Phagocytosis and epithelial cell invasion by Crohn’s disease-associated adherent-invasive Escherichia coli are inhibited by the anti-inflammatory drug 6-mercaptopurine. Frontiers in Microbiology, 9(MAY), 1–15. https://doi.org/10.3389/fmicb.2018.00964
38. Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V, Reyes, J. A., Shah, S. A., Leleiko, N., Snapper, S. B., Bousvaros, A., Korzenik, J., Sands, B. E., Xavier, R. J., & Huttenhower, C. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
39. Muzes, G., Molnár, B., Tulassay, Z., & Sipos, F. (2012). Changes of the cytokine profile in inflammatory bowel diseases. World Journal of Gastroenterology, 18(41), 5848–5861. https://doi.org/10.3748/wjg.v18.i41.5848
40. Nash, A. K., Auchtung, T. A., Wong, M. C., Smith, D. P., Gesell, J. R., Ross, M. C., Stewart, C. J., Metcalf, G. A., Muzny, D. M., Gibbs, R. A., Ajami, N. J., & Petrosino, J. F. (2017). The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome, 5(1), 153. https://doi.org/10.1186/s40168-017-0373-4
41. Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., Sung, J. J. Y., & Kaplan, G. G. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet, 390(10114), 2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0
42. Nguyen, H. T. T., Dalmasso, G., Müller, S., Carrière, J., Seibold, F., & Darfeuille-Michaud, A. (2014). Crohn’s disease-associated adherent invasive escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology, 146(2), 508–519. https://doi.org/10.1053/j.gastro.2013.10.021
43. Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2018). Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, 11(1). https://doi.org/10.1007/s12328-017-0813-5
44. Orel, R., & Trop, T. K. (2014). Intestinal microbiota , probiotics and prebiotics in inflammatory bowel disease. 20(33), 11505–11524. https://doi.org/10.3748/wjg.v20.i33.11505
45. Palmela, C., Chevarin, C., Xu, Z., Torres, J., Sevrin, G., Hirten, R., Barnich, N., Ng, S. C., & Colombel, J. F. (2018). Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 67(3), 574–587. https://doi.org/10.1136/gutjnl-2017-314903
46. Petersen, C., & Round, J. L. (2014). Microreview Defining dysbiosis and its influence on host immunity and disease. 16(June), 1024–1033. https://doi.org/10.1111/cmi.12308
47. Pu, D., Zhang, Z., & Feng, B. (2022). Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Frontiers in Pharmacology, 13(June). https://doi.org/10.3389/fphar.2022.906419
48. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., … Zoetendal, E. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464(7285), 59–65. https://doi.org/10.1038/nature08821
49. Qusty, N., Sarhan, A., Taha, M., Alshanqiti, A., Almuteb, A. M., Alfaraidi, A. T., Alkhairi, H. A., Alzahrani, M. M., Alamry, A. H. A., Qalil, T., Alomry, B., Bannan, O. A., & Almaashi, M. S. (2024). The Role of Gut Microbiota in the Efficacy and Side Effect Profile of Biologic Therapies for Autoimmune Diseases. 16(10), 1–9. https://doi.org/10.7759/cureus.71111
50. Rashed, R., Valcheva, R., & Dieleman, L. A. (2022). Manipulation of Gut Microbiota as a Key Target for Crohn’s Disease. Frontiers in Medicine, 9(June). https://doi.org/10.3389/fmed.2022.887044
51. Reinecker, H., Steffen, M., Witthoeft, T., Pflueger, I., & Schreiber, S. (1993).
52. Reyes, A., Haynes, M., Hanson, N., Angly, F. E., Heath, A. C., Rohwer, F., & Gordon, J. I. (2010). Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature, 466(7304), 334–338. https://doi.org/10.1038/nature09199
53. Ridlon, J. M., Kang, D., & Hylemon, P. B. (2006). review Bile salt biotransformations by human intestinal bacteria. 47, 241–259. https://doi.org/10.1194/jlr.R500013-JLR200
54. Round, J. L., & Mazmanian, S. K. (2010a). Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. 2010. https://doi.org/10.1073/pnas.0909122107/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.0909122107
55. Round, J. L., & Mazmanian, S. K. (2010b). Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. 2010. https://doi.org/10.1073/pnas.0909122107
56. Samuel, B. S., & Gordon, J. I. (2006). A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proceedings of the National Academy of Sciences of the United States of America, 103(26), 10011–10016. https://doi.org/10.1073/pnas.0602187103
57. Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008). Role of cytokines in inflammatory bowel disease. World Journal of Gastroenterology, 14(27), 4280–4288. https://doi.org/10.3748/wjg.14.4280
58. Satsangi, J., Kennedy, N. A., Henderson, P., Wilson, D. C., & Nimmo, E. R. (2011). Exploring the hidden heritability of inflammatory bowel disease. Gut, 60(11), 1447–1448. https://doi.org/10.1136/gutjnl-2011-300804
59. Sender, R., Fuchs, S., & Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biology, 14(8), 1–14. https://doi.org/10.1371/journal.pbio.1002533
60. Shah, T., Baloch, Z., Shah, Z., Cui, X., & Xia, X. (2021). The intestinal microbiota: Impacts of antibiotics therapy, colonization resistance, and diseases. International Journal of Molecular Sciences, 22(12). https://doi.org/10.3390/ijms22126597
61. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). Review The Central Nervous System and the Gut Microbiome. Cell, 167(4), 915–932. https://doi.org/10.1016/j.cell.2016.10.027
62. Singh, N., & Bernstein, C. N. (2022). Environmental risk factors for inflammatory bowel disease. United European Gastroenterology Journal, 10(10), 1047–1053. https://doi.org/10.1002/ueg2.12319
63. Sitaraman, S. V. (2008). IL-6 Induces NF-. 171(2003), 3194–3201.
64. Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P., & Doraé, J. (2009). Low counts of faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases, 15(8), 1183–1189. https://doi.org/10.1002/ibd.20903
65. Sousa, R. S. (2014). Caraterização do Acesso ao Centro Hospitalar Lisboa Norte , EPE Caraterização do Acesso ao Centro Hospitalar Lisboa Norte , EPE. 104(18).
66. Tenaillon, O., Skurnik, D., Picard, B., & Denamur, E. (2010). The population genetics of commensal Escherichia coli. Nature Reviews Microbiology, 8(3), 207–217. https://doi.org/10.1038/nrmicro2298
67. Thursby, E., & Juge, N. (2017). Introduction to the human gut microbiota. Biochemical Journal, 474(11), 1823–1836. https://doi.org/10.1042/BCJ20160510
68. Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1
69. Turroni, F., Milani, C., Duranti, S., Ferrario, C., Lugli, G. A., Mancabelli, L., van Sinderen, D., & Ventura, M. (2018). Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cellular and Molecular Life Sciences, 75(1), 103–118. https://doi.org/10.1007/s00018-017-2672-0
70. Wang, K., Wu, L. Y., Dou, C. Z., Guan, X., Wu, H. G., & Liu, H. R. (2016). Research Advance in Intestinal Mucosal Barrier and Pathogenesis of Crohn’s Disease. Gastroenterology Research and Practice, 2016. https://doi.org/10.1155/2016/9686238
71. Wexler, H. M. (2007). Bacteroides: The good, the bad, and the nitty-gritty. Clinical Microbiology Reviews, 20(4), 593–621. https://doi.org/10.1128/CMR.00008-07
72. Wright, E. K., Kamm, M. A., Teo, S. M., Inouye, M., Wagner, J., & Kirkwood, C. D. (2015). Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn ’ s Disease : A Systematic Review. 21(6), 1219–1228. https://doi.org/10.1097/MIB.0000000000000382
73. Wu, N., Mah, C., Koentgen, S., Zhang, L., Grimm, M. C., El-Omar, E., & Hold, G. L. (2021). Inflammatory bowel disease and the gut microbiota. Proceedings of the Nutrition Society, 80(4), 424–434. https://doi.org/10.1017/S002966512100197X
74. Zhao, S., Lieberman, T. D., Poyet, M., Kauffman, K. M., Gibbons, S. M., Groussin, M., Xavier, R. J., & Alm, E. J. (2019). Adaptive Evolution within Gut Microbiomes of Healthy People. Cell Host and Microbe, 25(5), 656-667.e8. https://doi.org/10.1016/j.chom.2019.03.007
75. Zuo, T., & Ng, S. C. (2018). The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. 9(September), 1–13. https://doi.org/10.3389/fmicb.2018.02247
Article Sidebar
Published
Jun 29, 2025
Article Details
How to Cite
Reshu Gaur, Navnit Rajput, Darshan Ambiga, Akansha Jha, Pooja Dixit, Jagjeet Singh, & Narotam Sharma. (2025). ASSOCIATION BETWEEN MICROBES AND IBD (CROHN’S DISEASE) AND THEIR SENSITIVITY/RESISTANCE TO DRUGS. Journal of Population Therapeutics and Clinical Pharmacology, 32(6), 183-194. https://doi.org/10.53555/cxhhv167
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Reshu Gaur
DNA Labs -A Centre for Applied Sciences, East Hope Town, Dehradun, Uttarakhand, India
Navnit Rajput
Department of Microbiology, School of Life Sciences, Khandari Campus, Dr. Bhimrao Ambedkar University, Agra, Uttar Pradesh, India
Darshan Ambiga
DNA Labs -A Centre for Applied Sciences, East Hope Town, Dehradun, Uttarakhand, India
Akansha Jha
Amity Institute of Virology and Immunology, Amity University Noida, Uttar Pradesh, India
Pooja Dixit
Department of Microbiology, School of Life Sciences, Khandari Campus, Dr. Bhimrao Ambedkar University, Agra, Uttar Pradesh, India
Jagjeet Singh
DNA Labs -A Centre for Applied Sciences, East Hope Town, Dehradun, Uttarakhand, India
Narotam Sharma
DNA Labs -A Centre for Applied Sciences, East Hope Town,Department of Chemistry, Uttaranchal Institute of Technology, Uttaranchal University Dehradun, Uttarakhand, India
How to Cite
Reshu Gaur, Navnit Rajput, Darshan Ambiga, Akansha Jha, Pooja Dixit, Jagjeet Singh, & Narotam Sharma. (2025). ASSOCIATION BETWEEN MICROBES AND IBD (CROHN’S DISEASE) AND THEIR SENSITIVITY/RESISTANCE TO DRUGS. Journal of Population Therapeutics and Clinical Pharmacology, 32(6), 183-194. https://doi.org/10.53555/cxhhv167